MDM2 and breast carcinoma: We aim to expand on our prior work and analyze the GATA3mut mutational landscape based on ctDNA next generation sequencing (NGS), and furthermore, we analyze GATA3mut proteomic data to understand the mechanism behind the efficacy of MDM2 inhibition in GATA3mut HR +/HER2− breast cancer.